SCHEMBL6749254

SCHEMBL6749254

CC(C)(C)OC(=O)N1CC2CCC(O)CC2C1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.60
CHRM2 P08172 1/20 0.49
CHRM1 P11229 1/20 0.49
CHRM3 P20309 1/20 0.49
PREP P48147 4/20 0.45
JAK1 P23458 2/20 0.42
JAK2 O60674 1/20 0.42
HPGD P15428 1/20 0.41
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GPR119 Q8TDV5 2/20 0.40
RECQL P46063 1/20 0.39
EPHX1 P07099 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20031433 1.00 NR1H2 (0.60) NR1H2CHRM2CHRM1CHRM3PREP
SCHEMBL20031051 1.00 NR1H2 (0.60) NR1H2CHRM2CHRM1CHRM3PREP
SCHEMBL20031049 1.00 NR1H2 (0.60) NR1H2CHRM2CHRM1CHRM3PREP
SCHEMBL30598863 1.00 NR1H2 (0.60) NR1H2CHRM2CHRM1CHRM3PREP
SCHEMBL12620805 0.92 NR1H2 (0.57) NR1H2CHRM2CHRM1CHRM3PREP
SCHEMBL24740662 0.90 NR1H2 (0.68) NR1H2CHRM2CHRM1CHRM3PREP
SCHEMBL904134 0.90 NR1H2 (0.68) NR1H2CHRM2CHRM1CHRM3PREP
SCHEMBL4409452 0.90 NR1H2 (0.68) NR1H2CHRM2CHRM1CHRM3PREP
SCHEMBL20936755 0.90 NR1H2 (0.68) NR1H2CHRM2CHRM1CHRM3PREP
SCHEMBL20566533 0.90 NR1H2 (0.68) NR1H2CHRM2CHRM1CHRM3PREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049419-A1 PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS GENZYME CORPORATION (US) 2025-03-06 WO disclosed
CN-117377675-A Bruton's tyrosine kinase degradation agent containing parallel ring or spiro ring 正大天晴药业集团股份有限公司 2024-01-09 CN disclosed
EP-3312164-B1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE CALITOR SCIENCES LLC (US) 2020-12-09 EP disclosed
US-20190002452-A1 FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD. (CN) 2019-01-03 US disclosed
EP-3401315-A1 FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF Guangzhou Henovcom Bioscience Co. Ltd. (CN) 2018-11-14 EP disclosed
EP-3312164-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE Calitor Sciences, LLC (US) 2018-04-25 EP disclosed
EP-3122729-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE Calitor Sciences, LLC (US) 2017-02-01 EP disclosed
CN-103304552-B Substituted pyridine compounds and using method thereof and purposes 广东东阳光药业有限公司 2016-12-28 CN disclosed
US-9403801-B2 Substituted heteroaryl compounds and methods of use CALITOR SCIENCES, LLC (US) 2016-08-02 US disclosed
US-20150274704-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-10-01 US disclosed
WO-2015148867-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2015-10-01 WO disclosed
WO-2013138210-A1 SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE XI NING (US) 2013-09-19 WO disclosed
CN-103304552-A Substituted pyridine compounds, methods of use and uses thereof GUANGDONG HEC PHARMACEUTICAL 2013-09-18 CN disclosed
US-20040092737-A1 Benzopiperidine derivatives EISAI CO., LTD. 2004-05-13 US disclosed
US-6518423-B1 These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and EISAI CO., LTD. (JP) 2003-02-11 US disclosed
EP-0934941-A1 BENZOPIPERIDINE DERIVATIVES Eisai Co., Ltd. (JP) 1999-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002452-A1 FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF NR1H4, FXR1, GPBAR1 NR1H2 6/4885CHRM2 1681/4885CHRM1 1576/4885
US-20040092737-A1 Benzopiperidine derivatives HLA-DRB1, HRH1, HRH2 NR1H2 301/4885CHRM2 1292/4885CHRM1 765/4885
US-20150274704-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE PRKACA, PRKDC, PRKACB NR1H2 976/4885CHRM2 4058/4885CHRM1 4558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.